Table 7.

Hazard Ratios (95% CI) for ASCVD Events Across Concordant/Discordant Groups by JUPITER Cut Points: The ARIC Study

Lipid Target Groups	hsCRP	ASCVD events, n/Individuals, n	Model 1 HR (95% CI)	Model 2 HR (95% CI)	Model 3 HR (95% CI)	Model 4 HR (95% CI)
Triple lipids < cut point	<2 mg/L	252/2208	REF	REF	REF	REF
(n=4709)	≥2 mg/L	398/2501	1.60 (1.36–1.89)	1.45 (1.21–1.73)	1.41 (1.18–1.68)	1.40 (1.17–1.68)
Triple lipids ≥ cut point	<2 mg/L	215/1294	REF	REF	REF	REF
(n=3140)	≥2 mg/L	392/1846	1.46 (1.24–1.73)	1.27 (1.06–1.54)	1.27 (1.05–1.53)	1.26 (1.04–1.52)
Quadruple lipids < cut point	<2 mg/L	189/1797	REF	REF	REF	N/A
(n=3765)	≥2 mg/L	279/1968	1.52 (1.25–1.84)	1.43 (1.15–1.76)	1.39 (1.12–1.72)	N/A
Quadruple lipids ≥ cut point	<2 mg/L	172/1956	REF	REF	REF	N/A
(n=3371)	≥2 mg/L	322/1415	1.45 (1.20–1.75)	1.28 (1.04–1.58)	1.28 (1.04–1.57)	N/A

hsCRP <2 mg/L groups are reference. Triple lipids: LDL‐C + non–HDL‐C + apolipoprotein B. Quadruple lipids: LDL‐C + non–HDL‐C + apolipoprotein B + TC/HDL‐C. Cut points: LDL‐C: 130 mg/dL (percentile 57), non–HDL‐C: 160 mg/dL, apolipoprotein B: 102 mg/dL, TC/HDL: 4.4, HDL‐C: 50 mg/dL, hsCRP: 2 mg/L. Model 1: adjusted for age, sex, race/center. Model 2: Model 1 + physical activity + smoking status + body mass index + systolic blood pressure + treatment for hypertension + diabetes mellitus + lipid‐lowering medication use. Model 3: Model 2 + log‐triglycerides. Model 4: Model 3 + log‐HDL‐C. International System of Units conversion factors: To convert total, LDL‐C, and HDL‐C to mmol/L, multiply by 0.0249. To convert triglycerides to mmol/L, multiply by 0.0113. ARIC indicates Atherosclerosis Risk in Communities; ASCVD, atherosclerotic cardiovascular disease; HDL‐C, high‐density lipoprotein cholesterol; HR, hazard ratio; hsCRP, high‐sensitivity C‐reactive protein; JUPITER, Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin; LDL‐C, low‐density lipoprotein cholesterol; N/A indicates not applicable; TC, total cholesterol.